ESPR

Esperion Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website esperion.com
Employees(FY) 199
ISIN US29664W1053

Performance

+23.02%

+52.71%

+69.4%

+43.52%

+3.68%

YTD

+101.3%

Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Advanced Technical Analysis

Technical Analysis of ESPR 2024-12-02

The stock exhibits a strong bullish sentiment with a Moving Average Score of 96, indicating robust upward momentum, while the Technical Score of 75 further supports this positive outlook. However, the Oscillators Score of 53 suggests a neutral stance, indicating potential consolidation or a pause in the upward trend, which investors should monit...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ESPR

Stock Rank

Recent News & Updates

2024-12-01 19:00
Esperion Announces New Drug Submissions in Canada for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk(Globenewswire)
2024-11-26 09:03
Esperion Therapeutics' Bempedoic Acid Submitted for Approval in Japan by Otsuka Pharmaceutical(MT Newswires)
2024-11-26 08:00
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia(GlobeNewswire)
2024-11-25 19:00
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia(Globenewswire)
2024-11-21 08:00
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference(GlobeNewswire)
2024-11-20 19:00
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference(Globenewswire)
2024-11-18 10:30
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024(GlobeNewswire)
2024-11-17 21:30
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024(Globenewswire)
2024-11-08 16:15
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(GlobeNewswire)
2024-11-08 03:15
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(Globenewswire)
2024-11-07 13:08
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...(Yahoo Finance)
2024-11-07 10:58
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y(Zacks)
2024-11-06 18:10
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates(Yahoo Finance)
2024-11-06 17:08
Esperion Therapeutics: Q3 Earnings Snapshot(Yahoo Finance)
2024-11-06 17:00
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-11-03 19:00
Esperion to Participate in Upcoming Jefferies London Healthcare Conference(Globenewswire)
2024-10-30 22:01
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release(Yahoo Finance)
2024-10-30 20:00
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions(Globenewswire)
2024-10-23 20:00
Esperion to Report Third Quarter 2024 Financial Results on November 7(Globenewswire)
2024-10-17 07:02
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings(Yahoo Finance)
2024-10-02 16:56
Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?(Yahoo Finance)
2024-10-01 20:00
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid(Globenewswire)
2024-09-25 04:30
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)(Globenewswire)
2024-09-10 23:30
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?(Yahoo Finance)
2024-09-04 20:00
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference(Globenewswire)
2024-09-02 20:00
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe)(Globenewswire)
2024-08-25 20:00
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-12 13:06
Q2 2024 Esperion Therapeutics Inc Earnings Call(Yahoo Finance)
2024-08-11 23:44
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year(Yahoo Finance)
2024-08-11 19:10
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates(Yahoo Finance)

Page 1 of 8

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.